Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor (BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia (CLL). The lymphocytosis experienced by most patients under ibrutinib has previously been attributed to inhibition of BTK...

Descripción completa

Detalles Bibliográficos
Autores principales: Tissino, Erika, Benedetti, Dania, Herman, Sarah E.M., ten Hacken, Elisa, Ahn, Inhye E., Chaffee, Kari G., Rossi, Francesca Maria, Dal Bo, Michele, Bulian, Pietro, Bomben, Riccardo, Bayer, Elisabeth, Härzschel, Andrea, Gutjahr, Julia Christine, Postorino, Massimiliano, Santinelli, Enrico, Ayed, Ayed, Zaja, Francesco, Chiarenza, Annalisa, Pozzato, Gabriele, Chigaev, Alexandre, Sklar, Larry A., Burger, Jan A., Ferrajoli, Alessandra, Shanafelt, Tait D., Wiestner, Adrian, Del Poeta, Giovanni, Hartmann, Tanja Nicole, Gattei, Valter, Zucchetto, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789417/
https://www.ncbi.nlm.nih.gov/pubmed/29301866
http://dx.doi.org/10.1084/jem.20171288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789417/
https://www.ncbi.nlm.nih.gov/pubmed/29301866
http://dx.doi.org/10.1084/jem.20171288

Ejemplares similares